Log In
Print this Print this

siponimod (BAF312)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSecond-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist
Molecular Target Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing-remitting multiple sclerosis (RRMS); Treat secondary progressive multiple sclerosis (SPMS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today